Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | BTK | Q06187 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | ACACB | O00763 | 5/20 | 0.40 |
| ▸ | CTSS | P25774 | 2/20 | 0.40 |
| ▸ | CTSK | P43235 | 2/20 | 0.40 |
| ▸ | ACACA | Q13085 | 3/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | CKS1B | P61024 | 1/20 | 0.38 |
| ▸ | SKP1 | P63208 | 1/20 | 0.38 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17915686 | 0.91 | KMT2A (0.46) | EPHX1KMT2ADRD2ACACBCTSS | |
| SCHEMBL6647123 | 0.91 | EPHX1 (0.48) | EPHX1BTKKMT2ADRD2ACACB | |
| SCHEMBL228180 | 0.87 | EPHX1 (0.50) | EPHX1BTKKMT2ADRD2ACACB | |
| SCHEMBL23562337 | 0.85 | KMT2A (0.43) | EPHX1BTKKMT2ADRD2ACACB | |
| SCHEMBL23562349 | 0.85 | KMT2A (0.43) | EPHX1BTKKMT2ADRD2ACACB | |
| SCHEMBL13579957 | 0.85 | KMT2A (0.44) | EPHX1BTKKMT2ADRD2ACACB | |
| SCHEMBL14548191 | 0.85 | EPHX1 (0.43) | EPHX1BTKKMT2ADRD2ACACB | |
| SCHEMBL30772783 | 0.85 | EPHX1 (0.43) | EPHX1BTKKMT2ADRD2ACACB | |
| SCHEMBL7817045 | 0.85 | EPHX1 (0.43) | EPHX1BTKKMT2ADRD2ACACB | |
| SCHEMBL13781382 | 0.85 | KMT2A (0.44) | EPHX1BTKKMT2ADRD2ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7638546-B1 | Imidazolyl derivatives | IPSEN PHARMA S.A.S. (FR) | 2009-12-29 | — | — | US | disclosed |
| EP-1465880-B1 | 5-SULPHANYL-4H-1,2,4-TRIAZOLE DERIVATIVES AND THEIR USE TO TREAT DISORDERS ASSOCIATED WITH SOMATOSTATINE | IPSEN PHARMA (FR) | 2009-08-05 | — | — | EP | disclosed |
| US-7566734-B2 | Imidazolyl derivatives | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S. (FR) | 2009-07-28 | — | — | US | disclosed |
| US-20070299073-A1 | Imidazolyl derivatives | IPSEN PHARMA S.A.S. (FR) | 2007-12-27 | — | — | US | disclosed |
| US-20070032653-A1 | N-{1-(4-(3-bromophenyl)-1H-imidazol-2-yl)-5-methylhexyl}-N-cyclohexylamine; agonists or antagonists of somatostatin receptors; acromegaly, restenosis, Crohn's disease, systemic sclerosis, external and internal pancreatic pseudocysts and ascites, nesidoblastosis, hyperinsulinism, gastrinoma, etc. | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S. (FR) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299073-A1 | Imidazolyl derivatives | SSTR5, SSTR3, SSTR2 | EPHX1 4350/4885BTK 2164/4885KMT2A 3454/4885 |
| US-20070032653-A1 | N-{1-(4-(3-bromophenyl)-1H-imidazol-2-yl)-5-methylhexyl}-N-cyclohexylamine; agonists or antagonists of somatostatin receptors; acromegaly, restenosis, Crohn's disease, systemic sclerosis, external and internal pancreatic pseudocysts and ascites, nesidoblastosis, hyperinsulinism, gastrinoma, etc. | GHSR, IGF1R, GIPR | EPHX1 3844/4885BTK 2890/4885KMT2A 2496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.